DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05147896

SAMAS

UnknownPhase NA

Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

100

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•Morphological arterial wall characteristics•Functional arterial wall characteristics•Structural arterial wall characteristics

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05147896
Org study IDUMCLjubljana20210043

Timeline

Milestones

Study first posted2021-12-07actual
Study start2022-05-01actual
Last update posted2022-05-24actual
Primary completion2023-05-01estimated
Study completion2023-12-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age30 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•type 2 diabetes
•therapy including at least metformin 1000 mg and sulphonyl urea at least half of the maximal dose
•BMI > or = 30 kg/m2
•HbA1c < or = 8,5%
•associated risk factors including smoking, dyslipidaemia, arterial hypertension, chronic kidney disease stage 1 to 3.

Exclusion criteria

•therapy with injectable GLP-1 receptor agonist ongoing or was taking place in the last year
•manifested cardiovascular disease
•heart failure
•chronic kidney disease stages 4 and 5
•advanced liver disease
•proliferative retinopathy or maculopathy

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
5
Glycemic / diabetes
1
Other (unclassified)
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in glycated haemoglobin (HbA1c)

Time frame:1 year

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

5 endpoints
Primary/protocol endpoint

Change in morphological arterial wall characteristics

Time frame:1 year

change from baseline, improvement

Primary/protocol endpoint

Change in functional arterial wall characteristics

Time frame:1 year

change from baseline, improvement

Primary/protocol endpoint

Change in structural arterial wall characteristics

Time frame:1 year

change from baseline, improvement

Secondary/protocol endpoint

Change in atherogenic small dense low-density lipoproteins (sdLDL)

Time frame:1 year

change from baseline, improvement

Secondary/protocol endpoint

Change in high sensitivity C-reactive protein (hsCRP)

Time frame:1 year

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Correlations between changes in rate of cIMT reduction, % of endothelial function improvement and rate of arterial stiffness reduction on one hand and changes in concentration of sdLDL, % of HbA1c and concentration of hsCRP on the other

Time frame:1 year

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.